Watch Dr Christopher Cannon discuss his study: Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
[template part=”video”]
Register your email and provide your feedback
To help measure the effectiveness of this NOAC Education module, please enter your email below to take part in a short follow-up survey[template part=”speaker”]
Topic
In patients with atrial fibrillation who have had a percutaneous coronary intervention, the current standard practice is to prescribe “triple therapy” i.e. warfarin plus two antiplatelet agents including an aspirin. However, this is associated with a high risk of bleeding. This ground-breaking trial compares triple therapy with “dual therapy” (dabigatran plus one antiplatelet agent).
View abstract access full paper
[template part=”details”]
